Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 8 Oct, 25 | ACET | Buy | USD 0.85 | USD 0.9 | USD 0.95 | Same day | Closed |
14.86%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Controlled Overall Operating Expenses: Total operating expenses declined slightly by 1%, from USD 32.8 million in Q2 FY2024 to USD 32.4 million in Q2 FY2025, despite a 10% increase in R&D investment
Significant Reduction in Administrative Costs: General and Administrative (G&A) expenses decreased 43% year-over-year, from USD 6.9 million in Q2 FY2024 to USD 4.0 million in Q2 FY2025, saving approximately USD 2.9 million
Sharp Decline in Interest Income: Interest income decreased by 53%, from USD 3.0 million in Q2 FY2024 to USD 1.4 million in Q2 FY2025, resulting in a USD 1.6 million shortfall
Widening Net Loss: Net loss increased by 4%, from USD 29.9 million in Q2 FY2024 to USD 31.2 million in Q2 FY2025
Adicet Bio faces a material investment risk stemming from its reliance on external financing to sustain R&D operations amid continued losses and declining cash reserves, which may lead to shareholder dilution or funding constraints if capital markets remain unfavorable.
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 0.85 | 0.75 | 0.9 | 0.95 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Financial Performance Overview: For the quarter ended June 30, 2025 (Q2 FY2025), Adicet Bio recorded a net loss of USD 31.2 million, compared to USD 29.9 million in the prior-year quarter (Q2 FY2024), marking a 4% year-over-year increase. Total operating expenses were relatively flat at USD 32.4 million in Q2 FY2025, against USD 32.8 million in Q2 FY2024, indicating effective cost containment despite higher clinical activity. The loss per share stood at USD 0.34, marginally up from USD 0.33 in the previous year, primarily reflecting lower interest income and a higher share base.
Research and Development Investment: Research and development (R&D) expenses rose 10% year-over-year, from USD 25.9 million in Q2 FY2024 to USD 28.4 million in Q2 FY2025. This increase was mainly due to higher external development costs linked to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), as well as additional facility-related costs. However, the rise was partially offset by reduced payroll and lower stock-based compensation. The growth in R&D reflects the company’s continued progress in advancing ADI-001 for autoimmune indications and ADI-212, its PSMA-targeted oncology candidate.
Administrative Efficiency and Cost Management: General and administrative (G&A) expenses decreased by 43% year-over-year, from USD 6.9 million in Q2 FY2024 to USD 4.0 million in Q2 FY2025. The decline was primarily driven by lower personnel costs and reduced stock-based compensation, alongside facility cost optimizations. This marked improvement highlights management’s focus on operational efficiency, ensuring that resources are prioritized toward core research programs amid ongoing market challenges.
Non-Operating Income and Other Expenses: Interest income declined sharply by 53%, falling from USD 3.0 million in Q2 FY2024 to USD 1.4 million in Q2 FY2025, mainly due to lower cash balances and moderating yields on short-term investments. Additionally, other expenses rose from USD 0.05 million to USD 0.22 million, a 337% increase, largely resulting from higher franchise taxes and minor equipment losses. The combined impact of reduced interest income and increased miscellaneous costs marginally widened the net loss during the quarter.
Liquidity and Balance Sheet Position: The company’s liquidity position weakened over the past year, with cash, cash equivalents, and short-term investments totaling USD 124.9 million as of June 30, 2025, compared to USD 224.1 million as of June 30, 2024 — a 44% decline. Total stockholders’ equity also fell by 29%, from USD 186.6 million at December 31, 2024, to USD 133.4 million at June 30, 2025. Adicet expects continued operating losses in the near term, driven by ongoing clinical development and manufacturing costs, and may require additional equity or debt financing to sustain operations beyond its current cash runway.
Strategic Realignment: In July 2025, Adicet announced a 30% workforce reduction and a pipeline prioritization initiative, emphasizing ADI-001 and ADI-212 as core assets while discontinuing ADI-270. The realignment is expected to incur one-time restructuring costs of approximately USD 2.3 million in Q3 FY2025, aimed at extending the company’s cash runway and improving long-term R&D efficiency. This restructuring underscores management’s focus on maintaining strategic flexibility and optimizing capital deployment in a constrained funding environment.
As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to Adicet Bio, Inc (NASDAQ: ACET) at the closing market price of USD 0.85 as of Oct 07,2025.
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACET Adicet Bio Inc |
0.02 3.35% | 0.49 | - | - | 9.72 | 0.35 | 2.14 | -1.2112 |
| NVO Novo Nordisk A/S |
-0.005 0.01% | 47.77 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.05 0.10% | 47.83 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.53% | 447.15 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.52 0.60% | 745.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 07,2025. The reference data in this report has been partly sourced from REFINITIV.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2023 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
